INS and diabetes mellitus: A leading cause of CKD is long-standing diabetes, which leads to diabetic nephropathy; the 2017 randomized clinical trial by Leiter et al. showed that patients with Type 1 and Type 2 Diabetes Mellitus (DM) who were on insulin benefitted from the introduction of alirocumab in addition to statins or alirocumab as a monotherapy in patients who are statin intolerant [17].